Akeso, Inc. (AKESF)
OTCMKTS · Delayed Price · Currency is USD
16.20
+0.09 (0.59%)
Oct 16, 2025, 9:30 AM EDT
Akeso Employees
Akeso had 3,035 employees as of December 31, 2024. The number of employees increased by 257 or 9.25% compared to the previous year.
Employees
3,035
Change (1Y)
257
Growth (1Y)
9.25%
Revenue / Employee
$99,313
Profits / Employee
-$33,464
Market Cap
14.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,035 | 257 | 9.25% |
Dec 31, 2023 | 2,778 | 437 | 18.67% |
Dec 31, 2022 | 2,341 | 476 | 25.52% |
Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
Dec 31, 2020 | 746 | 356 | 91.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
American Oncology Network | 1,914 |
Jushi Holdings | 1,234 |
Glass House Brands | 374 |
Silence Therapeutics | 116 |
Elite Pharmaceuticals | 68 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
The Greater Cannabis Company | 1 |
Akeso News
- 25 days ago - Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer - PRNewsWire
- 4 weeks ago - Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML) - PRNewsWire
- 4 weeks ago - Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma - PRNewsWire
- 5 weeks ago - Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC - PRNewsWire
- 6 weeks ago - Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy - PRNewsWire
- 7 weeks ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 7 weeks ago - Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs - PRNewsWire
- 7 weeks ago - Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints - PRNewsWire